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The formylpeptide receptor-1 (FPR1) is a member of the chemotactic GPCR-7TM formyl peptide 
receptor family, whose principle function is in trafficking of various leukocytes into sites of bacterial 
infection and inflammation. More recently, FPR1 has been shown to be expressed in different types 
of cancer and in this context, plays a significant role in their expansion, resistance and recurrence. 
ICT12035 is a selective and potent (30 nM in calcium mobilisation assay) small molecule FPR1 
antagonist. Here, we demonstrate the efficacy of ICT12035, in a number of 2D and 3D proliferation 
and invasion in vitro assays and an in vivo model. Our results demonstrate that targeting FPR1 by a 
selective small molecule antagonist, such as ICT12035, can provide a new avenue for the treatment of 
cancers.
The formylpeptide receptors, of which there are three isoforms, FPR1, FPR2 (formerly known as FPRL1 and 
also known as ALX) and FPR3 (formerly known as FPRL2), belong to the cell surface chemotactic GPCR-7TM 
family. FPRs are primarily involved in leukocyte migration to the sites of bacterial  infections1. For example, 
FPR1, which is the most common of the three, is expressed on a variety of leucocytes including monocytes and 
 macrophages2,3,  neutrophils2,3, immature dendritic  cells4, natural killer  cells5, and T  cells6. Leukocytes respond 
after their FPR1 receptors are activated by molecules which are released at the site of infection as a result of 
bacterial or tissue necrosis and  damage7,8. These molecules include short chain N-formylated peptides such as 
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLF)9,10 and annexin A1 (ANXA1)11,12.
More recently, investigations have revealed that FPR1 also plays an important role in cancer. Although the 
expression of FPR1 in healthy, non-immune human cells is  low13–15, it has been shown that a number of tumours 
express significant levels of FPR1. These include high grade  glioblastoma16–18,  neuroblastoma19,  colon13,20,  breast21, 
and  bladder22 cancers. We should however note that in gastric cancer the role of FPR1 remains ambiguous. 
While FPR1 expression has been associated with poor prognosis in gastric cancer and correlated with tumour 
stage in one  report23, another report suggested FPR1 expression suppresses gastric cancer angiogenesis and cor-
relates with  survival24,25. In addition, FPR1 is shown to contribute to the expansion of different tumour types. 
For instance, knock down of FPR1 reduces the ability of glioblastoma U87-MG tumour xenografts to  grow26. 
Ye has shown that  FPR1-/- mice have increased survival compared with  FPR+/+ littermates in a colorectal cancer 
 model20. Finally, Vecchi and Goulart have shown that immunosuppressant cyclosporine A, which is also a weak 
antagonist of FPR1  (IC50 = 2–4 μM in calcium mobilisation  assay27), retards tumour growth and invasiveness in 
a breast cancer in vivo  model21. Whilst these studies suggest a direct role for FPR1 in tumour growth, evidence 
in  ovarian28,  glioma17 and bladder  cancers22 as well as acute lymphoblastic  leukaemia29, has suggested that FPR1 
is also involved in resistance and recurrence.
In spite of the accumulating evidence supporting a role for FPR1 in cancer, as yet no small molecule specifi-
cally targeting FPR1 has been tested for in vivo efficacy in a tumour model. ICT12035 belongs to a class of previ-
ously published, potent and selective family of FPR1  antagonists30 which are now being further investigated in 
our lab. ICT12035 is a potent  (IC50 = 30 nM in a calcium mobilisation assay), selective (> 100 fold versus FPR2), 
and non-cytotoxic (cell viability above 95 ± 5% at 100 μM) FPR1 antagonist (see Supplementary Information). 
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Here we show that ICT12035 reduces proliferation and invasion of cancer cell lines in a number of 2D and 3D 
assays, and retards growth of tumours in an in vivo xenograft model.
Results
FPR1 is expressed in cancer cell lines, and its expression is elevated in the periphery of 
tumour’s hypoxic/necrotic foci. We first determined the protein level expression of FPR1 in various 
cancer cell lines, using flow cytometry. Expression of FPR1 was detected in the following human cancer cell lines: 
U87-MG (glioblastoma), PC-3, DU-145, LnCap (prostate), SH-SY-5Y (neuroblastoma), K-562 (chronic myelog-
enous leukaemia), HCT-116, SW620, SW480 and HT-29 (colorectal), A549 (lung) and MDA-MB-231 (breast) 
(Fig. 1A). We also showed that that in addition to being present in these cell lines, the receptor is functionally 
active and responds to FPR1 agonist fMLF in a  Ca2+ mobilisation assay (Fig. 1B). Furthermore, this response to 
fMLF is abrogated by the selective and potent FPR1 antagonist, ICT12035 (Fig. 1B, only PC-3, SH-SY-5Y and 
HCT-116 data are shown as examples).
Walenkamp has previously shown that expression of FPR1 in human glioblastoma cells depends on the 
tumour  microenvironment31. In view of this, we also confirmed the expression of FPR1 in cancer cells grown as 
xenografts in mice by immunohistochemistry (IHC) (Fig. 1C, PC-3 and DU145 are shown as examples) (Fig. 1C).
We chose to study the efficacy of FPR1 antagonist ICT12035 in vitro and in vivo in the glioblastoma cell line, 
U87-MG. As we discussed earlier, the relevance of FPR1 as a target is shown in a number of  cancers13,16–26,28,29. 
However, the expression and the relevance of FPR1 in glioblastoma is established in multiple  sources31,32. In 
addition focusing on new treatment approaches to glioma is important, as it remains a particularly challenging 
cancer to treat. U87-MG cells do express FPR1 (Fig. 1A) and also respond to both known agonists of FPR1, fMLF 
 (EC50 = 80 nM in calcium flux) (Fig. 1D) and ANXA1(2–26)  (EC50 = 1 μM in calcium flux, in a dose dependant 
manner in a calcium flux assay. A dose response curve in calcium mobilisation assay (also known as calcium 
flux assay) showed ICT12035 antagonised the activation of FPR1 receptor by 100 nM fMLF with an  IC50 of 
30 nM (Fig. 1E).
Before using the U87-MG cell line as an in vitro model, we decided to investigate the expression of FPR1 
in this cell line in 2D as well as 3D models. It is already known that 3D models such as multicellular spheroids 
recapitulate the conditions experienced by cancer cells within tumours’ hypoxic/necrotic regions, more closely 
than in 2D models, such as monolayer cells.
Indeed, we found that the level of FPR1-expression in U87-MG cell line in 2D culture increased under hypoxic 
and serum deprivation stress conditions, which correlate to those experienced within the tumour’s core (Fig. 2A). 
Furthermore, we investigated the expression of FPR1 in sections from formalin-fixed paraffin-embedded (FFPE) 
spheroids of U87-MG cells. In smaller spheroids with diameter below 400 micron, the levels of expression of 
FPR1 remained uniform across the whole section. However, in spheroids with diameter greater than 500 micron, 
which did contain a necrotic core (Fig. 2B–D), we observed a higher level of FPR1 expression in the periphery of 
the hypoxic/necrotic core of the spheroids. To determine if the same observation applies in vivo, we examined 
the levels of expression of FPR1 in U87-MG cells grown as subcutaneous xenografts. Again, we observed a higher 
level of FPR1 expression in the periphery of the hypoxic/necrotic core of the xenoplanted tumour (Fig. 2E).
ANXA1 is released from the hypoxic/necrotic core of 3D U87-MG multicellular spheroids. It 
has been previously established that ANXA1 is present in the supernatant of artificially necrotised glioma cells 
and that ANXA1 protein within these necrotic supernatant, can stimulate tumour cell growth and migration 
through binding to FPR1  receptor16,33. In view of this and our earlier observation that FPR1 expression is ele-
vated in the periphery of the hypoxic/necrotic core of spheroids, we wanted to determine if ANXA1 is also 
released from the hypoxic/necrotic core of spheroids. Using ELISA, we quantified and compared the levels of 
ANXA1 in the supernatant of U87-MG cells grown as 3D spheroids and as 2D monolayers (Fig. 3A). We con-
firmed a correlation between the quantity of excreted ANXA1 in the medium and the number of cells in both 
2D (monolayer) and 3D (spheroid) systems. However, the cell culture supernatants containing spheroids con-
tained more ANXA1 than those with the same number of corresponding cells cultured as monolayer and that 
difference increased for larger spheroids. The larger spheroids were subsequently isolated and shown to contain 
a bigger hypoxic/necrotic core. This observation strongly supports the hypothesis that ANXA1 released from 
the hypoxic/necrotic core diffuses out of spheroids’ core and can activate the FPR1 receptors which are in the 
periphery cells of the hypoxic/necrotic core. Furthermore, we confirmed the previous observation that ANXA1 
is expressed in the U87-MG cells grown as subcutaneous xenografts (Fig. 3B,C).
ICT12035 reduces fMLF-induced increases in proliferation in 2D and 3D culture. We next 
showed that activation of the FPR1 receptor results in increased proliferation in U87-MG cells. Addition of 
fMLF, which is a more potent agonist of FPR1 than ANXA1, to U87-MG cells grown as monolayers increased 
rate of cell proliferation. However, administration of the selective FPR1 antagonist ICT12035, at the same time 
as fMLF, abrogated the observed increase in cell numbers (Fig. 4A).
As 2D models do not accurately recapitulate the conditions experienced by cells within tumours, we also 
measured growth of U87-MG multicellular spheroids as determined by increases in their volume. Pre-formed 
spheroids with diameters in the range of 100–120 microns (n = 8) were treated with fMLF and control, and with 
ICT12035 and control (Fig. 3B). The spheroids’ growth was monitored by measuring the total volume of each 
spheroid at 146 h, 172 h and 197 h using a Celigo Imaging Cytometer (Nexcelom)34. We observed a statistically 
significant increase in the spheroid volume at both 172 h and 197 h upon fMLF treatment compared to control. 
However, that increase was significantly retarded upon addition of ICT12035 (Fig. 4B).
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Figure 1.  (A) Fold expression of FPR1 over control (isotype antibody) in different cell lines as determined 
by flow cytometry. (B) Relative fluorescence response in  Ca2+ mobilisation (flux) assay to FPR1 agonist 
fMLF (100 nM) in the presence or absence of FPR1 antagonist ICT12035 (1 μM) for cell lines PC3, HCT-116 
and SH-SY-5Y. (C) Expression of FPR1 by immunohistochemistry (IHC) in sections from PC3 and DU145 
xenotransplanted tumour tissue (with and without antibody). Basophilic structure of cell was stained in blue 
with haematoxylin solution. (D) Dose response curve for U87-MG cells over concentration range of fMLF 
(agonist mode). (E) Dose response curve for U87-MG cells over concentration range of ICT12035 after 
treatment with 100 nM fMLF (antagonist mode).
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To correlate the FPR1 mediated increase in proliferation to necrosis, we also treated U87 cells with superna-
tant from necrotized cells which we and  others16,33 have shown to contain ANXA1. U87 cells were necrotized 
using a freeze–thaw  cycle33. The supernatant was centrifuged to remove cell debris and was then filtered. Treat-
ment of U87 cells with this necrotic supernatant also resulted in an upsurge in proliferation, which again could 
be reduced upon addition of FPR1 antagonist ICT12035 (Fig. 4C).
ICT12035 reduces fMLF-induced increases in U87-MG cell invasion in 2D and 3D culture. We 
next looked at the role of FPR1 antagonism in modulating invasiveness of U87-MG cells in 2D and 3D culture. 
In a Boyden assay, using inserts coated with collagen, ICT12035 retards the invasion of U87-MG cells in a dose 
dependant manner (Fig. 5A,B). We also investigated effectiveness of ICT12035 on invasiveness of U87-MG mul-
ticellular spheroids. The spheroids were stained with calcein for ease of detection, embedded in collagen (with 
and without fMLF) and analysed at 18 and 39 h by microscopy. At both time points, we observed larger cross 
section area for the spheroids embedded in collagen containing 100 nM fMLF. Furthermore the increase was 
abrogated upon addition of ICT12035 (Fig. 5C,D).
Antagonism of FPR1 modulates growth of U87-MG xenotransplanted tumour in mice. Finally, 
we used a subcutaneous U87-MG xenograft model to assess in vivo efficacy of ICT12035. Prior to the efficacy 
experiments, non-tumour bearing mice (n = 4) were treated with escalating doses of ICT12035 and we observed 
no toxicity upto a maximum dose of 100  mg/Kg. Therefore, the drug was administered at 100  mg/Kg dose 
for five consecutive days to tumour bearing mice and the tumour growth was monitored compared to a con-
trol group (n = 8 for both). No signs of toxicity were evident, and encouragingly, we observed a six day delay 
(p < 0.05) in further growth of the tumours (Fig. 6).
Materials and methods
Cells and reagents. All cell lines were obtained from either the European Collection of Cell Cultures 
(ECACC) or American Type Cell Culture (ATCC) and maintained in recommended media supplemented with 
10% (v/v) foetal calf serum, 1 mM sodium pyruvate and 2 mM L-glutamine; at 37 °C in an atmosphere of 5% 
 CO2. All cell lines are authenticated in the past three years. ICT12035 was prepared in the laboratories of the 
Institute of Cancer Therapeutics, University of Bradford.
Figure 2.  (A) Expression of FPR1 in U87-MG cells, cultured as monolayers, in flow cytometry over isotype 
control, under normal cell culture condition, serum starvation, and hypoxia (* < 0.05, ** < 0.005, *** < 0.0005, 
**** < 0.0001). (B,D) Expression of FPR1 by IHC in sections from a U87-MG multicellular spheroid (bar = 200 
micron, 100 micron and 50 micron respectively). Basophilic structure of cell was stained in blue with 
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Flow cytometry. Two Eppendorfs containing 30–50 × 104 cells each were treated with 20 μL of anti-hFPR1 
(PE-conjugated, R&D system, FAB3744P) and mouse  IgG2A isotype control (PE-conjugated, R&D system, 
IC003G). Both tubes were incubated in the dark at 0 °C for 45 min. After washing with 1% BSA in PBS, the cells 
were analysed using a BD Accuri C6 plus flow cytometer.
Formation of spheroids. U87-MG cells (1 × 106 cells/ml) were seeded into a spinner flask (F7690, Techne, 
Bibby Scientific Limited, Staffordshire, UK) containing 150 mL of RPMI-1640 containing 10% FCS (v/v), and 
placed on a magnetic stirrer plate (MCS-104S, Techne, Bibby Scientific Limited, Staffordshire, UK). The mixture 
was stirred at a rate of 55 rpm for 5 days.
Immunohistochemistry. The 5 micron thick sections from FFPP blocks of xenoplanted tumour tissue or 
spheroids were incubated with the rabbit polyclonal FPR1 primary antibody (Abcam, ab113531).
Annexin A1 quantification using ELISA. This was carried out using a sandwich enzyme-linked immu-
nosorbent assay (ELISA) kit for human Annexin A1 purchased from Abcam (ab222868).
Preparation of necrotic supernatant. A suspension of about 55 × 104 cells/mL of U87-MG cell in PBS 
was subjected to 7 cycles of rapid freezing at − 80 °C and thawing at room temperature. The mixture was centri-
fuged and the supernatant was filtered to remove any debris.
Figure 3.  (A) Concentration of annexin A1 (ANXA1) released in the culture media surrounding U87-MG 
multicellular spheroid (grey) or over monolayer U87-MG cells (black) at different cell numbers. (B,C) 
Expression of ANXA1 by IHC in sections from a U87-MG xenotransplanted tumour tissue (with and without 
antibody). Basophilic structure of cell was stained in blue with haematoxylin solution.
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Cell viability assay using MTT. Into each well of the 96 well plates, 180 µL of U87-MG cell suspension 
(5 × 104 cells/mL) were seeded. 20 µL of either PBS (as control) or ICT12035 solution in increasing concentra-
tions were also added. Readings for each concentration were carried out in quadruplicate. Plates were incu-
bated at 37 °C, 5%  CO2, for 96 h. Then, 20 µL of a 5 g/L solution of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) (Alfa Aesar, L1193) in water was added. The plate was incubated at 37 °C, 5% 
 CO2 for 4 h after which, the solution was carefully removed and DMSO (150 µL) was added to dissolve the 
formazan crystals. The absorbance of each well was measured at 540 nm using a Multiscan Ex 96 well microplate 
reader (Thermo Electron Corporation, United Kingdom). The experiment was repeated in triplicate (n = 3).
Cell viability assay using cell counting. Into four wells of a 6-well plate, 1980 µL of U87-MG cell sus-
pension (5 × 104 cells/mL) were added. To one well was added 20 µL of PBS (control plate); to the second well was 
added 20 µL of fMLF in PBS to achieve an in well concentration of 100 nM; to the third well was added 20 µL 
of ICT12035 in PBS to achieve an in well concentration of 1 µM; and to the fourth well was added 10 µL of each 
ICT12035 and fMLF in PBS to achieve an in well concentration of 1 µM and 100 nM respectively. After 5 days, 
each well was treated with trypsin/EDTA solution until cells were fully detached, and viable cell numbers were 
counted (trypan blue exclusion). The experiment was repeated in triplicate (n = 3).
Spheroid growth assay. Spheroids were generated by adding 200 μL of a 2500 cell/mL U87-MG cell sus-
pension into each well of an ultralow adherence 96 microtiter plate (ULA-96U from Nexcelom). Spheroids were 
Figure 4.  (A) Number of viable U87-MG cell (trypan blue exclusion) after 4 days (number of cells at t = 0 days 
is 10,000) (n = 8). ICT12035 is not cytotoxic and has no effect on cell viability (second coloumn). Presence of 
100 nM fMLF significantly increases number of viable cells (third column) compared to control (first coloumn) 
(p = 0.039); however, addition of ICT12035 (1 µM) abrogates the fMLF induced increase in proliferation 
(p = 0.039) (* means p < 0.05) (B) Volume of U87-MG spheroids at 146 h, 172 h and 197 h (n = 8). ICT12035 is 
not cytotoxic and has no effect on spheroid growth (second coloumn). Presence of 100 nM fMLF significantly 
increases the spheroid growth (third column) compared to control (first coloumn) (p = 0.0031 at 197 h); 
however, addition of ICT12035 (1 μM) abrogates the fMLF induced increase in spheroid growth (p = 0.0014 
at 197 h) (** means p < 0.005) (C) Relative number of U87-MG cell after 4 days (relative number of cells at 
t = 0 days is 1) (n = 3). Presence of supernatant significantly increases number of cells (second column) compared 
to control (first coloumn) (p = 0.003); however, addition of ICT12035 (1 µM) abrogates the fMLF induced 
increase in proliferation (p = 0.011) (* means p < 0.05; ** means p < 0.005).
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formed after 48 h. The spheroids were treated once every 24 h with either PBS (as control), 100 nM fMLF, 1 μM 
ICT12035 (in well concentration) or both fMLF and ICT12035. The increase in the volume of spheroids were 
monitored for 9 days using a Celigo Imaging Cytometer using instruments  software34.
Calcium mobilisation assay. This was carried out by an adaptation of the recommended  protocol35. 
10 × 104 U87-MG cells were seeded into each well of a Corning tissue culture treated 96-well black polystyrene 
assay plate (VWR, 734–1609). After 24 h, the growth medium was removed and replaced with 100 µL of the dye 
loading solution (Molecular Probes Fluo-4 NW (no wash), Invitrogen F36206). The plates were incubated at 
37 °C for 30 min. 20 μL of a given concentration of the antagonist in assay buffer, or plain assay buffer as control 
was added to each well and the plate was incubated at 37 °C for another 30 min. The plate was transferred into a 
Fluoroskan Ascent FL instrument (ThermoScientific) and the fluorescence in response to the addition of 20 μL 
Figure 5.  (A) Relative number of migrated cell in a two chamber (Boyden) assay. 100 nM fMLF significantly 
increases number of migrated cells (second column) compared with when no fMLF is added (p < 0.0001). This 
fMLF-induced increase in migrated cells is abrogated in a dose dependent manner upon addition of ICT12035 
with significant reductions at 10 nM (p = 0.0398), 100 nM (p = 0.0043), 1 µM (p < 0.0001), 10 µM (p < 0.0001) 
and 100 µM (p < 0.0001) (* < 0.05, ** < 0.005, *** < 0.0005, **** < 0.0001). (B) Visual representation of differences 
in migration of U87-MG cells (stained with DAPI) in a Boyden assay. (C) Relative area of invasion for U87-MG 
spheroids embedded in collagen and maintained under cell culture medium. Addition of 9.14 µM fMLF to the 
cell culture medium significantly increases area of invasion (second column) compared with when no fMLF 
is added (p = 0.0031). This fMLF-induced increase in migrated cells is abrogated in a dose dependent manner 
upon addition of ICT12035 with significant reductions at 2 µM (p = 0.0002) and 20 µM (p = 0.0002) (* < 0.05, 
** < 0.005, *** < 0.0005, **** < 0.0001). (D) Visual representation of differences in migration of U87-MG 
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Figure 6.  (A) A comparison between the growth of established xenotransplanted tumours Treatment of 
mice with established xenotransplanted tumours (n = 8) with five intraperitoneally administered daily doses 
(100 mg/Kg) of ICT12035, resulted in a 6.1 days (p < 0.05) delay in tumour growth compared with control; (B) 
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of 100 nM fMLF (in well concentration) was measured at 37 °C (Ex 485 nm, Em 538 nm).  IC50 is calculated as 
the concentration of the antagonist required to half the maximal response to fMLF. The experiment was repeated 
in triplicate (n = 3).
Chemotaxis assay. Was performed in 24-well chemotaxis chamber inserts (Corning, Product code: 3415). 
The filters were coated with 50 μg/mL collagen type I solution from rat tail (Sigma, C3867). To the lower cham-
ber was added 600 μL of RPMI-1640 (no serum) containing either no agonist (control) or fMLF (1.62 µM). To 
the upper compartment were added 150 μL of U87-MG cells (6.7 × 105 cells/mL) containing the appropriate 
concentration of ICT12035. After 16 h, the medium was removed and replaced with ethanol to fix the cells. 
Using a cotton bud, the non-migrated cells in the top compartment were gently removed from the membrane. 
The membrane was allowed to air dry and then was removed using a scalpel. The membrane was mounted onto a 
slide using mounting medium containing DAPI (Vector Labs, VECTASHIELD hard set mounting medium with 
DAPI). The mounted slides were viewed under a fluorescent microscope with a LeikaDM2000 camera attached. 
Six images from varying fields at a 20 × magnification were taken. The images were analyzed using ImageJ soft-
ware 36. The result was given as the percentage average area of the image taken up by the DAPI stained (blue) 
nuclei. The experiment was repeated in triplicate (n = 3).
Spheroid invasion assay. 1 µL of Calcein AM (4 mM in DMSO) was added to U87-MG cell suspended 
in 10 mL RPMI-1640 containing 10% v/v foetal calf serum. After 30 min incubation at 37 °C, the cell suspen-
sion was centrifuged, and the supernatant discarded. The cells were resuspended in culture medium containing 
methyl cellulose (v/v 20%) to a concentration of 8 × 104 cells/mL. The lid of a 60 mm tissue culture dish was 
inverted, and 5 mL of PBS added to the bottom of the dish. A multi-channelled pipette was used to deposit 
25 µL drops (2000 cells) to the base of the lid. The lid was then inverted and placed onto the PBS-filled bottom 
chamber. The dish was incubated at 5%  CO2 and 37 °C for 24 h or until spheroids had formed. Ice cold aqueous 
sodium hydroxide (1 M, 108.33 µL) was added to an ice cold mixture of 5 × PBS (2 mL), distilled water (3.56 mL) 
and collagen I (from rat tail, Corning, 354236) (4.33 mL). This solution was equally divided between different 
Eppendorfs, and either PBS (control), fMLF to a final concentration of 9.14 μM, ICT12035 to a final concentra-
tion of 20 μM or fMLF (9.14 μM) and various concentrations of ICT12035 were added. The wells of a 96-well 
glass-bottomed black plate (Thermofisher, 160376) were covered with 40 µL of each of the three collagen mix-
tures which after warming to room temperature formed a gel. Single spheroids added onto each well containing 
a layer of collagen gel. Another 40 µL Collagen mix was gently added over the top of each spheroid to ensure the 
spheroid was encased in collagen gel. On top of the final layer of collagen gel was added serum free RPMI-1640 
(50 µL) to prevent the spheroids/gel from drying out. Images were taken at 0 h and 39 h using a LumaScope 500 
and the green fluorescence filter to detect the preloaded Calcien AM within the cells. The images were analysed 
using ImageJ  software36.
In vivo efficacy of ICT12035. All procedures were carried out under Project Licence PPL 40/3670 issued 
by the UK Home Office according to government legislation, following approval of the work by the local Animal 
Welfare Ethics Review Board at the University of Bradford, and in accordance with the UK National Cancer 
Research Institute Guidelines for the Welfare of  Animals37. Balb/c immunodeficient nude mice (Envigo, Lough-
borough, UK), between the ages of 6 and 8 weeks, were used. Under brief general inhalation anaesthesia 2 to 3 
 mm3 fragments of U87-MG human tumor xenografts were implanted subcutaneously in the abdominal flank of 
the mice. Once tumour volumes reached approximately 32  mm3 (as measured by callipers), this was designated 
as Day 0, and mice were randomised into two groups (n = 8). One group received ICT-12035 administered intra-
peritoneally at 100 mg/kg dose on days 0, 1, 2, 3 and 4. For comparison, the control group was left untreated. 
Tumour volume using callipers and animal body weight were recorded through the experiment and normalised 
to the respective volume on the initial day of treatment (day 0). Mann–Whitney U tests were conducted to 
determine the statistical significance of any differences in growth rate (based on tumour volume doubling time) 
between control and treated groups.
Discussion
Dysregulated and improper vascularisation during tumour growth reduces access to oxygen and nutrients in 
regions within the tumour resulting in the formation of hypoxic/necrotic foci within tumours. This tumour 
necrosis plays a multifaceted and complex role in many  tumours38–40. In particular, necrotised cells release many 
of their cytoplasmic molecules, which includes annexin A1 (ANXA1) protein, into the extracellular  milieu30,41–44. 
The release of these proinflammatory molecules recruits leukocytes to the tumour microenvironment. Interest-
ingly, the inflammatory response within tumours appears to both help and hinder tumour  expansion45.
In addition, ANXA1 appears to have a distinct tumour promoting effect by binding and activating FPR1, the 
expression of which is shown to be elevated in many  tumours13,16–22. The activation of FPR1 by ANXA1 promotes 
angiogenesis, proliferation, and invasion in a number of  cancers13,46. It follows that inhibiting the activation of 
FPR1 by ANXA1, may have a potential role as a therapy against a number of cancers. However, to date no small 
molecule FPR1 antagonist has ever been investigated as a potential cancer therapy. ICT12035 is a potent and 
selective small molecule FPR1  antagonist30. We set out to provide the proof of the principle that a small molecule 
FPR1 antagonist, such as ICT12035, can have a potential as a therapy for cancers such as glioma.
A substantial body of work has already shown that the expression of FPR1 is elevated in glioma, and that the 
expression correlates with the stage of  tumours16. More interestingly, Walenkamp has shown that the expres-
sion is enhanced under conditions within the tumour  microenvironment32. Our observation (Fig. 1) that FPR1 
expression is particularly elevated in the periphery of the necrotic/hypoxic core, both in a 3D spheroid model 
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and in xenografted tissue, strengthens the correlation of FPR1 axis to tumour necrosis. In tissue, the so called 
pseudopalisades are known to be rich in HIF-1α, carbonic anhydrase IX and MMPs and may be considered 
an invading front of aggressive glioma  tumours47. Although we have not yet investigated the drivers for the 
elevation of FPR1 expression in the periphery of the tumour core, we can speculate that may be partly due to 
hypoxia. Hypoxia is already known to elevate expression of another chemotactic receptor, CXCR4, in  glioma48. 
Furthermore, we and  others49 have shown that release of ANXA1 also correlates to hypoxia/necrosis which in 
turn may enhance FPR1 expression through an autocrine  loop21.
In assessment of the efficacy of ICT12035, we opted for the use 3D in vitro models such as spheroids. 3D 
in vitro models are generally more advantageous and relevant than 2D models, and provide more reliable  data50. 
Indeed, ICT12035 retards both proliferation and invasion of U87 spheroids as well as monolayers (Figs. 3 and 4). 
Furthermore, to show the relevance of necrosis to the FPR1-mediated expansion of gliomas, we used ICT12035 
to retard increases in both proliferation and invasion of U87 spheroids as well as monolayers by necrotic U87 
supernatants.
Finally, treatment of mice bearing xenotransplanted tumours with ICT12035 over 5 days, completely arrested 
growth of the tumours during the treatment period, but as expected, had no toxic side-effect on the mice.
Our further preliminary investigations, which we will report in due course, reveal similar effects of FPR1 
activation in other cancer types. This clearly demonstrates the usefulness of FPR1 antagonists, particularly 
in treatment aggressive tumours. Furthermore, it is known that necrosis results from a number of treatment 
modalities in cancers and is hypothesised to contribute to poor clinical outcomes of current  therapies39,51,52. This 
raises an interesting hypothesis that combining current therapies with antagonism of FPR1, at least in parts, 
may contribute to making them more efficacious. Therefore, further investigation of ICT12035, or other FPR1 
antagonists, can open opportunities for more efficient treatment for cancers, including glioma, in due course.
Data availability
The data generated during and/or analysed during the current study are available from the corresponding author 
on reasonable request.
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